IN2012DN03172A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03172A IN2012DN03172A IN3172DEN2012A IN2012DN03172A IN 2012DN03172 A IN2012DN03172 A IN 2012DN03172A IN 3172DEN2012 A IN3172DEN2012 A IN 3172DEN2012A IN 2012DN03172 A IN2012DN03172 A IN 2012DN03172A
- Authority
- IN
- India
- Prior art keywords
- dose
- human patient
- antibody
- dosage regimen
- present
- Prior art date
Links
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 abstract 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24365109P | 2009-09-18 | 2009-09-18 | |
| EP09170715 | 2009-09-18 | ||
| US34414710P | 2010-06-01 | 2010-06-01 | |
| EP10164596 | 2010-06-01 | ||
| PCT/EP2010/063795 WO2011033105A1 (en) | 2009-09-18 | 2010-09-20 | Dosage regimen for administering an epcamxcd3 bispecific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03172A true IN2012DN03172A (enrdf_load_stackoverflow) | 2015-09-25 |
Family
ID=43127167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3172DEN2012 IN2012DN03172A (enrdf_load_stackoverflow) | 2009-09-18 | 2010-09-20 |
Country Status (15)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
| AR089114A1 (es) | 2011-12-09 | 2014-07-30 | Amgen Res Munich Gmbh | PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| EP2956477B2 (en) | 2013-02-15 | 2024-01-24 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
| CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| US11046763B2 (en) * | 2014-01-08 | 2021-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| JP7073258B2 (ja) * | 2015-11-19 | 2022-05-23 | レビトープ リミテッド | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| CN116218863A (zh) | 2016-02-01 | 2023-06-06 | 比奥贝拉蒂治疗公司 | 优化的因子viii基因 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| WO2017167350A1 (en) * | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| BR112020004543A2 (pt) * | 2017-09-08 | 2020-09-08 | Maverick Therapeutics, Inc. | proteínas de ligação ativadas condicionalmente restritas |
| CN114390938B (zh) | 2019-03-05 | 2025-03-21 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
| JP2022549932A (ja) | 2019-09-30 | 2022-11-29 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| BR112022026127A2 (pt) | 2020-06-24 | 2023-01-17 | Bioverativ Therapeutics Inc | Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína |
| EP4435006A1 (en) * | 2021-11-19 | 2024-09-25 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| ATE493441T1 (de) | 2003-10-16 | 2011-01-15 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| ES2417065T3 (es) * | 2005-04-26 | 2013-08-05 | Trion Pharma Gmbh | Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer |
-
2010
- 2010-09-20 SG SG2012016044A patent/SG179027A1/en unknown
- 2010-09-20 WO PCT/EP2010/063795 patent/WO2011033105A1/en active Application Filing
- 2010-09-20 CA CA2774732A patent/CA2774732A1/en not_active Abandoned
- 2010-09-20 RU RU2012115480/15A patent/RU2012115480A/ru not_active Application Discontinuation
- 2010-09-20 EP EP10755167A patent/EP2477653A1/en not_active Withdrawn
- 2010-09-20 MX MX2012003175A patent/MX2012003175A/es not_active Application Discontinuation
- 2010-09-20 CN CN2010800523771A patent/CN102711825A/zh active Pending
- 2010-09-20 KR KR1020127007677A patent/KR20120083359A/ko not_active Withdrawn
- 2010-09-20 SG SG10201405434VA patent/SG10201405434VA/en unknown
- 2010-09-20 IN IN3172DEN2012 patent/IN2012DN03172A/en unknown
- 2010-09-20 BR BR112012008345A patent/BR112012008345A2/pt not_active IP Right Cessation
- 2010-09-20 NZ NZ598601A patent/NZ598601A/en not_active IP Right Cessation
- 2010-09-20 JP JP2012529298A patent/JP2013505223A/ja active Pending
- 2010-09-20 AU AU2010297258A patent/AU2010297258A1/en not_active Abandoned
- 2010-09-20 US US13/496,836 patent/US20120244161A1/en not_active Abandoned
-
2012
- 2012-03-14 IL IL218637A patent/IL218637A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL218637A0 (en) | 2012-05-31 |
| CA2774732A1 (en) | 2011-03-24 |
| CN102711825A (zh) | 2012-10-03 |
| EP2477653A1 (en) | 2012-07-25 |
| NZ598601A (en) | 2014-05-30 |
| US20120244161A1 (en) | 2012-09-27 |
| JP2013505223A (ja) | 2013-02-14 |
| SG179027A1 (en) | 2012-04-27 |
| RU2012115480A (ru) | 2013-10-27 |
| MX2012003175A (es) | 2012-04-11 |
| KR20120083359A (ko) | 2012-07-25 |
| WO2011033105A1 (en) | 2011-03-24 |
| AU2010297258A1 (en) | 2012-03-29 |
| SG10201405434VA (en) | 2014-10-30 |
| BR112012008345A2 (pt) | 2016-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG179027A1 (en) | Dosage regimen for administering an epcamxcd3 bispecific antibody | |
| NZ609201A (en) | Means and methods for treating dlbcl | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| MX354371B (es) | Régimen de dosificación para administrar un anticuerpo biespecífico cd19xcd3 a pacientes en riesgo de efectos adversos potenciales. | |
| SG179204A1 (en) | Dosage regimen for administering a cd19xcd3 bispecific antibody | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| MX362626B (es) | Métodos para tratar pacientes pediátricos usando dexmedetomidina.. | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| EP3501546A3 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| MY159353A (en) | Pirfenidone treatment for patients with atypical liver function | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| AU2010300611A8 (en) | Hematopoietic stem cells for use in the treatment of a kidney injury | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| MY190951A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| MX352647B (es) | Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato. | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| WO2012079093A3 (en) | Dosage and administration of bispecific scfv conjugates | |
| WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
| MX2016008397A (es) | Composicion para usarse en el tratamiento de tos persistente. | |
| IN2014DN09437A (enrdf_load_stackoverflow) | ||
| MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
| MX2022006054A (es) | Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos. |